MorningMed is a community of 814,300 medical professionals

We're a place where medical professionals share news and other news items to help their peers stay up to date

All articles tagged: Hypoglycemia, unspecified (E16.2)

HealthDay 20 June at 08.50 PM

Timing of Exercise Significant for Obesity, Metabolic Impairment

For sedentary adults with obesity/overweight and metabolic impairments, the timing of moderate-to-vigorous physical activity (MVPA) is significant, with a beneficial effect on glucose homeostasis for accumulation of more MVPA in the evening, according to a study published online June 10 in Obesity.Antonio Clavero-Jimeno, from the Univ

Evalytics 13 May at 08.50 PM

1 in 8 adults in the US has taken Ozempic or another GLP-1 drug, KFF survey finds

The article discusses a survey showing the rise in popularity of Ozempic, a GLP-1 drug, for type 2 diabetes. It highlights the drug's effectiveness and patient satisfaction, leading to increased prescriptions. However, concerns remain about its cost and accessibility for some patients.

HealthDay 16 January at 04.30 PM

Liraglutide Exerts Weight Loss-Independent, GLP-1R-Dependent Effects

Use of the glucagon-like peptide 1 receptor (GLP-1R) agonist liraglutide exerts weight loss-independent, GLP-1R-dependent effects on insulin sensitivity, according to a study published online Oct. 24 in Diabetes.Mona Mashayekhi, M.D., Ph.D., from Vanderbilt University Medical Center in Nashville, Tennessee, and colleagues examined whet

HealthDay 02 January at 11.53 PM

Eating Heart-Healthy Diet Before Cardiac Catheterization Is Safe

For patients undergoing elective cardiac catheterization, eating a heart-healthy diet prior to the procedure poses no safety risk, according to a study published online Jan. 1 in the American Journal of Critical Care.Carri Woods, R.N., from the Parkview Heart Institute in Fort Wayne, Indiana, and colleagues conducted a prospective rando

HealthDay 06 December at 10.55 PM

Eli Lilly Says Its New Weight-Loss Drug, Zepbound, Is Now Available

Eli Lilly has announced that its newly approved weight-loss medication, Zepbound, is now available for patients to take."Today opens another chapter for adults living with obesity who have been looking for a new treatment option like Zepbound," Rhonda Pacheco, group vice president of Lilly Diabetes and Obesity, U.S., said in a company news rel